ZA200600230B - Isethionate salt of a selective CDK4 ihibitor - Google Patents

Isethionate salt of a selective CDK4 ihibitor

Info

Publication number
ZA200600230B
ZA200600230B ZA200600230A ZA200600230A ZA200600230B ZA 200600230 B ZA200600230 B ZA 200600230B ZA 200600230 A ZA200600230 A ZA 200600230A ZA 200600230 A ZA200600230 A ZA 200600230A ZA 200600230 B ZA200600230 B ZA 200600230B
Authority
ZA
South Africa
Prior art keywords
ihibitor
selective cdk4
isethionate salt
isethionate
salt
Prior art date
Application number
ZA200600230A
Other languages
English (en)
Inventor
Beylin Vladimir Genukh
Erdman David Thomas
Blackburn Anthony Clyde
Toogood Peter Laurence
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA200600230B publication Critical patent/ZA200600230B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200600230A 2003-07-11 2006-01-10 Isethionate salt of a selective CDK4 ihibitor ZA200600230B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48635103P 2003-07-11 2003-07-11

Publications (1)

Publication Number Publication Date
ZA200600230B true ZA200600230B (en) 2007-04-25

Family

ID=34062121

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200600230A ZA200600230B (en) 2003-07-11 2006-01-10 Isethionate salt of a selective CDK4 ihibitor

Country Status (32)

Country Link
US (2) US7345171B2 (zh)
EP (1) EP1648889B1 (zh)
JP (1) JP4053073B2 (zh)
KR (1) KR100816945B1 (zh)
CN (1) CN1835951B (zh)
AR (1) AR045898A1 (zh)
AT (1) ATE412650T1 (zh)
AU (1) AU2004255934B2 (zh)
BR (1) BRPI0412516A (zh)
CA (1) CA2532049C (zh)
CL (1) CL2004001701A1 (zh)
CY (1) CY1108589T1 (zh)
DE (1) DE602004017474D1 (zh)
DK (1) DK1648889T3 (zh)
ES (1) ES2313016T3 (zh)
GT (1) GT200400130A (zh)
HK (1) HK1091205A1 (zh)
IL (1) IL173034A (zh)
MX (1) MXPA06000484A (zh)
NL (1) NL1026624C2 (zh)
NO (1) NO335100B1 (zh)
NZ (1) NZ544609A (zh)
PA (1) PA8606501A1 (zh)
PE (1) PE20050700A1 (zh)
PL (1) PL1648889T3 (zh)
PT (1) PT1648889E (zh)
RU (1) RU2317296C2 (zh)
SI (1) SI1648889T1 (zh)
TW (1) TWI288750B (zh)
UY (1) UY28404A1 (zh)
WO (1) WO2005005426A1 (zh)
ZA (1) ZA200600230B (zh)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
KR101538412B1 (ko) * 2005-10-07 2015-07-22 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
EP2069344A2 (en) * 2006-09-08 2009-06-17 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010513317A (ja) * 2006-12-14 2010-04-30 パナシー ファーマシューティカルズ インコーポレーティッド サイクリン依存性キナーゼの阻害による神経保護方法
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
MX2010006457A (es) * 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
ATE531372T1 (de) * 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
CA2738925A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
AU2009310352A1 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2519526B1 (en) 2009-12-31 2014-03-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Tricyclic compounds for use as kinase inhibitors
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
CN103501789A (zh) 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US8741491B2 (en) * 2011-06-17 2014-06-03 Fluidic, Inc. Ionic liquid containing sulfonate ions
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN105008357A (zh) * 2013-02-21 2015-10-28 辉瑞大药厂 选择性cdk4/6抑制剂的固态形式
JP6435315B2 (ja) 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
RS59790B1 (sr) 2013-03-15 2020-02-28 G1 Therapeutics Inc Privremena zaštita normalnih ćelija tokom hemoterapije
EA201892726A1 (ru) * 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CN105294682B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP3174878A4 (en) * 2014-07-31 2017-12-27 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
WO2016024249A1 (en) * 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
MX2017009270A (es) 2015-02-03 2017-10-11 Jiangsu Hengrui Medicine Co Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
CN104910149A (zh) * 2015-04-28 2015-09-16 上海百奇医药科技有限公司 一种Palbociclib制备方法
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
JP6400196B2 (ja) * 2015-05-29 2018-10-03 帝人ファーマ株式会社 ピリド［３，４−ｄ］ピリミジン誘導体及びその薬学的に許容される塩
SI3302565T1 (sl) * 2015-06-04 2020-02-28 Pfizer Inc. Trdne farmacevtske oblike palbocikliba
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
ES2741958T3 (es) * 2015-08-05 2020-02-12 Ratiopharm Gmbh Nueva forma cristalina y aductos de ácido acético de palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
HU230962B1 (hu) * 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106800554A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二盐酸盐的晶型及其制备方法
CN106800553A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二羟乙基磺酸盐的晶型
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017172734A1 (en) * 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Treating cancer metastasis
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JP6870082B2 (ja) * 2016-07-07 2021-05-12 プランテックス・リミテッド 二メシル酸パルボシクリブの固体形態
MD3497103T2 (ro) 2016-08-15 2021-08-31 Pfizer Inhibitori de piridopirimidinonă CDK2/4/6
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
EP3528812B1 (en) 2016-10-20 2020-12-30 Pfizer Inc Palbociclib for treating pah
WO2018091999A1 (en) 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
UA124273C2 (uk) * 2016-11-28 2021-08-18 Тейдзін Фарма Лімітед КРИСТАЛІЧНА ФОРМА ПІРИДО[3,4-d]ПІРИМІДИНОВОГО ПОХІДНОГО АБО ЙОГО СОЛЬВАТ
KR102576011B1 (ko) 2017-01-06 2023-09-06 쥐원 쎄라퓨틱스, 인크. 암의 치료를 위한 조합 요법
MX2019010202A (es) 2017-03-03 2019-10-02 Seattle Genetics Inc Compuestos que interactuan con glicano y metodos de uso.
US20200054560A1 (en) * 2017-04-21 2020-02-20 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
EP3658119A1 (en) 2017-07-28 2020-06-03 Synthon B.V. Pharmaceutical composition comprising palbociclib
CA3088381A1 (en) * 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
US20200405809A1 (en) 2018-02-27 2020-12-31 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
PL3793609T3 (pl) 2018-05-14 2024-05-13 Pfizer Inc. Preparat w postaci doustnego roztworu
AU2019310335A1 (en) 2018-07-23 2021-02-11 F. Hoffmann-La Roche Ag Methods of treating cancer with PI3K inhibitor, GDC-0077
SG11202101807SA (en) 2018-08-24 2021-03-30 G1 Therapeutics Inc Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
EP3863618A1 (en) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
US20230053328A9 (en) 2019-05-24 2023-02-16 Pfizer Inc. Combination therapies using cdk inhibitors
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
KR20220108085A (ko) 2019-12-03 2022-08-02 제넨테크, 인크. 유방암 치료를 위한 병용 요법
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
TW202216131A (zh) 2020-07-15 2022-05-01 美商輝瑞大藥廠 用於癌症治療之ｋａｔ６抑制劑方法及組合
EP4181919A1 (en) 2020-07-20 2023-05-24 Pfizer Inc. Combination therapy
WO2022063119A1 (zh) * 2020-09-24 2022-03-31 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
WO2023107525A1 (en) 2021-12-10 2023-06-15 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302755A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
JP2024067010A (ja) 2022-11-02 2024-05-16 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271611A1 (en) * 2000-09-01 2002-03-22 Glaxo Group Limited Oxindole derivatives
ATE323706T1 (de) * 2001-12-17 2006-05-15 Smithkline Beecham Corp Pyrazolopyridazinderivate
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
US7767701B2 (en) * 2002-11-22 2010-08-03 Glaxosmithkline Llc Chemical compounds
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US7507834B2 (en) * 2003-02-27 2009-03-24 Smithkline Beechan Corporation Substituted anilinopyrazoles

Also Published As

Publication number Publication date
KR100816945B1 (ko) 2008-03-25
TW200516079A (en) 2005-05-16
NZ544609A (en) 2008-07-31
MXPA06000484A (es) 2006-04-05
ES2313016T3 (es) 2009-03-01
BRPI0412516A (pt) 2006-09-19
NO20060386L (no) 2006-04-05
NO335100B1 (no) 2014-09-15
JP4053073B2 (ja) 2008-02-27
CA2532049C (en) 2010-07-20
US7345171B2 (en) 2008-03-18
CY1108589T1 (el) 2014-04-09
NL1026624C2 (nl) 2005-07-20
EP1648889B1 (en) 2008-10-29
WO2005005426A1 (en) 2005-01-20
US7863278B2 (en) 2011-01-04
DK1648889T3 (da) 2009-01-05
CA2532049A1 (en) 2005-01-20
US20050059670A1 (en) 2005-03-17
CL2004001701A1 (es) 2005-06-03
TWI288750B (en) 2007-10-21
UY28404A1 (es) 2005-02-28
PE20050700A1 (es) 2005-10-18
IL173034A0 (en) 2006-06-11
PT1648889E (pt) 2008-12-10
RU2006101052A (ru) 2006-07-27
US20080021037A1 (en) 2008-01-24
AR045898A1 (es) 2005-11-16
CN1835951B (zh) 2010-06-02
JP2007530425A (ja) 2007-11-01
NL1026624A1 (nl) 2005-01-12
RU2317296C2 (ru) 2008-02-20
IL173034A (en) 2010-06-16
PL1648889T3 (pl) 2009-03-31
ATE412650T1 (de) 2008-11-15
GT200400130A (es) 2005-07-14
HK1091205A1 (en) 2007-01-12
PA8606501A1 (es) 2005-03-03
AU2004255934B2 (en) 2010-02-25
CN1835951A (zh) 2006-09-20
KR20060054300A (ko) 2006-05-22
SI1648889T1 (sl) 2009-02-28
DE602004017474D1 (de) 2008-12-11
EP1648889A1 (en) 2006-04-26
AU2004255934A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
ZA200600230B (en) Isethionate salt of a selective CDK4 ihibitor
EP1659933A4 (en) METHOD FOR CONSTRUCTING A BIOSENSOR
HK1139681A1 (en) Salts of valsartan
GB2403489B (en) Expandable tubulars
AU157139S (en) Toilet
IL174592A0 (en) Processes for the preparation of a polymorph of fluvastantin sodium
GB0423522D0 (en) Method of abandoning a well
EP1676835A4 (en) METHOD FOR PRODUCING TRIARYL SULPHONIUM SALTS
PL360722A1 (en) Lavatory-bidet bowl
AU155005S (en) Bidet
GB0402479D0 (en) Toilet
GB2428721B (en) Expandable tubulars
GB0312139D0 (en) Bowls
GB0309120D0 (en) A set of parts
GB2430952B (en) Methods of forming a centraliser
AU157275S (en) A set of bowls
GB2399657B (en) Alarm clock
GB0207286D0 (en) Salt
GB0326554D0 (en) Serfer of a wall
SE0302451D0 (sv) a new salt
GB2430987B (en) A method of forming a boss
GB0206255D0 (en) Novel salt forms
PL362493A1 (en) Design of three-dimensional structures
AU155726S (en) Bowl
AU154873S (en) A set of bowls